ATORX 2,37 SEK (3,49 %) 02 Dec 2021 17:29 SV ABOUT ALLIGATOR RESEARCH & DEVELOPMENT CORPORATE GOVERNANCE INVESTORS NEWS CONTACT Start > Investors > Financial reports > Interim reports Share and shareholders Calendar Analysts IPO Financial reports Annual reports Interim reports Preferential rights issue Q1 2021 Preferential Rights Issue Q4 2021 Presentations Interim reports 2021 2020 2019 2018 2017 2016 21 Oct 2021 Alligator Bioscience AB: Interim report January–September 2021 13 Jul 2021 Alligator Bioscience AB: Interim report January–June 2021 27 Apr 2021 Alligator Bioscience AB: Interim report January–March 2021 18 Mar 2021 Alligator Bioscience publishes Annual Report for 2020 26 Feb 2021 Alligator Bioscience AB: Year-end Report January-December 2020 About Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies. Links About Alligator Research and development Corporate governance Investors News Contact Privacy policy Contact Alligator Bioscience AB Medicon Village Scheelevägen 2 SE-223 81 Lund Sweden Phone: + 46 (0)46 540 82 00 info@alligatorbioscience.com ir@alligatorbioscience.com Subscribe Subscribe to get our pressreleases by email. SUBSCRIBE © Copyright 2018 - Alligator Bioscience AB